Are stable postoperative biliary atresia patients really stable?

Area of Science:

• Hepatology
• Immunology
• Biochemistry

Background:

• Transforming growth factor-beta 1 (TGF beta-1) is a key mediator in liver-cell proliferation and hepatic fibrosis (HF).
• Hepatic stellate cells (HSC) are activated by TGF beta-1 and are central to fibrogenesis.
• Biliary atresia (BA) is a condition where early diagnosis and monitoring are crucial for patient outcomes.

Purpose of the Study:

• To investigate the correlation between serum TGF beta-1, activated HSC, and liver biochemistry in postoperative biliary atresia (BA) patients.
• To determine the value of TGF beta-1 as a clinical status indicator in postoperative BA.
• To assess the progression of hepatic fibrosis in BA patients.

Main Methods:

• Serum TGF beta-1 levels were measured using ELISA in 32 postoperative BA patients and 13 controls.
• Liver biopsy specimens were analyzed for TGF beta-1 and alpha-smooth muscle actin (SMA) to detect activated HSC.
• BA patients were categorized into three groups based on liver function tests (LFTs).

Main Results:

• Serum TGF beta-1 was significantly higher in BA patients with normal LFTs (Group I) and elevated transaminases (Group II) compared to end-stage patients (Group III) and controls.
• Strong positivity for TGF beta-1 and activated HSC (SMA) was observed in liver biopsies from Groups I and II.
• The presence of bile lakes in Group II patients correlated with the highest serum TGF beta-1 levels.

Conclusions:

• Progressive fibrogenesis occurs in postoperative BA patients, even when liver function tests appear normal.
• Serum TGF beta-1 and activated HSC are indicators of active fibrosis and fibrogenesis.
• Bile lakes are a critical sign of progressive hepatic fibrosis in BA patients, warranting extreme caution.